Cumberland Pharmaceu (CPIX) Stock Price, Quote & News

Company Profile

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, an...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 615 255 0068

Fax: 615 255 0094

Website: www.cumberlandpharma.com

Address:

1600 West End Avenue, Suite 1300, Nashville, United States

haha1978 Mar. 20 at 6:34 PM

$CPIX IPF has been updated on the NIH website. Looks like January of next year 2027 its completed. https://clinicaltrials.gov/study/NCT05571059?tab=study

1 · Reply

haha1978 Mar. 20 at 6:30 PM

$CPIX SCL study is not due till May 2026. https://clinicaltrials.gov/study/NCT02682511

1 · Reply

BioResearcher Mar. 20 at 6:05 PM

$CPIX I no longer wait for them to release the SSC and IPF data. Just like they did not release the important DMD OLE data. SSC data has finished many moons ago, but still not out. Are they holding back failed data? We may never find out....

0 · Reply

BioResearcher Mar. 20 at 5:32 PM

$CPIX Vol is only 14K so far. I think this stock is mainly traded by the winners from CAPR :-) Like @haha1978 and few others. :-)

0 · Reply

haha1978 Mar. 19 at 7:21 PM

$CPIX 3.00 tomorrow or therabouts would be a great end to the week for a spinning top. The algorithm painting the tape for next week.

1 · Reply

BioResearcher Mar. 19 at 1:50 PM

$CPIX Oops ! spoke too soon. someone just woke up and dumped some shares to make it red now. Biotech stocks are getting killed lately, not only this one.

1 · Reply

BioResearcher Mar. 19 at 1:47 PM

$CPIX only green stock today !

0 · Reply

2pumps1dump Mar. 19 at 8:56 AM

$CPIX thought this was close

0 · Reply

BioResearcher Mar. 18 at 7:55 PM

$CPIX Without funding, I think they are likely to put the DMD drug on the shelf. Good OLE DMD data is likely to spike SP, but they don't publish it, Why ? Transparency is in question here.

1 · Reply

haha1978 Mar. 18 at 5:48 PM

$CPIX also market cap is around or below 40 million. If revenue can hit 55 to 60 million this year and be profitable thst could justify 5 to 8 dollars. Excluding ifetroban.

1 · Reply

Cumberland Pharmaceuticals Launches New Sancuso® Website Featuring Educational Resources for Chemotherapy-Induced Nausea and Vomiting

Mar 3, 2026, 5:00 PM EST - 18 days ago

CUMBERLAND PHARMACEUTICALS REPORTS 31% FOURTH QUARTER 2025 REVENUE GROWTH

Feb 25, 2026, 7:00 AM EST - 24 days ago

Joint U.S. Commercialization of RedHill's Talicia® Commences

RDHL

Feb 25, 2026, 7:00 AM EST - 24 days ago

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

Feb 24, 2026, 4:05 PM EST - 25 days ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE 2025 ANNUAL FINANCIAL RESULTS & COMPANY UPDATE

Feb 4, 2026, 9:05 AM EST - 6 weeks ago

Cumberland Pharmaceuticals Receives FDA Fast Track Designation for its Ifetroban Duchenne Muscular Dystrophy Program

Dec 8, 2025, 9:05 AM EST - 3 months ago

CALDOLOR® (IBUPROFEN) INJECTION CMS ISSUED J-CODE NOW ASSOCIATED WITH REIMBURSEMENT PRICE SUPPORTING NON-OPIOID PAIN MANAGEMENT

Nov 4, 2025, 5:00 PM EST - 4 months ago

CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH

Oct 28, 2025, 4:05 PM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE

Oct 20, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

RDHL

Oct 20, 2025, 9:00 AM EDT - 5 months ago

RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

Oct 13, 2025, 9:05 AM EDT - 5 months ago

CUMBERLAND PHARMACEUTICALS' VIBATIV® ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.

Oct 1, 2025, 9:05 AM EDT - 6 months ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO

Sep 29, 2025, 9:05 AM EDT - 6 months ago

TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA

Aug 5, 2025, 4:05 PM EDT - 8 months ago

Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date

Aug 4, 2025, 9:05 AM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK

Jul 29, 2025, 4:05 PM EDT - 8 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q2 2025 FINANCIAL RESULTS & COMPANY UPDATE

Jun 23, 2025, 9:05 AM EDT - 9 months ago

Cumberland Pharmaceuticals Shares Phase 2 FIGHT DMD Trial Results at the Parent Project Muscular Dystrophy Annual Conference

May 27, 2025, 4:05 PM EDT - 10 months ago

NEW STUDY FINDS CALDOLOR® SAFE AND EFFECTIVE FOR OPIOID-SPARING PAIN MANAGEMENT IN OLDER ADULTS

May 13, 2025, 4:05 PM EDT - 11 months ago

CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH

May 6, 2025, 4:05 PM EDT - 11 months ago

Cumberland Pharmaceuticals Reports 38% Revenue Growth in Q1 2025

Apr 29, 2025, 4:05 PM EDT - 11 months ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q1 2025 FINANCIAL RESULTS & COMPANY UPDATE

Mar 19, 2025, 4:05 PM EDT - 1 year ago

FIGHT DMD Trial Results Selected for Late-Breaking Presentation at MDA Clinical & Scientific Conference

Mar 4, 2025, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports 11.6% Fourth Quarter 2024 Revenue Growth

Feb 25, 2025, 4:05 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS

Feb 18, 2025, 7:30 AM EST - 1 year ago

VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA

Feb 4, 2025, 1:31 PM EST - 1 year ago

Cumberland Pharmaceuticals' Duchenne Candidate Shows Improved Heart Function In Patients With Associated Heart Disease

Feb 4, 2025, 7:30 AM EST - 1 year ago

Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease

Dec 10, 2024, 12:08 PM EST - 1 year ago

Why Is Cumberland Pharmaceuticals Stock Trading Over 100% on Tuesday?

Dec 9, 2024, 4:05 PM EST - 1 year ago

FDA APPROVES ACETADOTE® sNDA

Nov 7, 2024, 4:05 PM EST - 1 year ago

Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update

Nov 6, 2024, 5:21 PM EST - 1 year ago

CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY

Nov 5, 2024, 4:05 PM EST - 1 year ago

New Study Compares Caldolor® (ibuprofen injection) to ketorolac

Oct 31, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2024 FINANCIAL RESULTS

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024

Jul 30, 2024, 4:05 PM EDT - 1 year ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2024 FINANCIAL RESULTS

May 7, 2024, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update

Apr 30, 2024, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Apr 2, 2024, 4:05 PM EDT - 2 years ago

NEW REPORT SUPPORTS USE OF CALDOLOR® AS A STANDARD OF CARE ACROSS PATIENT POPULATIONS

Mar 5, 2024, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Annual 2023 Financial Results

Feb 27, 2024, 4:05 PM EST - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Nov 7, 2023, 4:05 PM EST - 2 years ago

Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results

Oct 31, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Oct 10, 2023, 4:05 PM EDT - 2 years ago

NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGE

Aug 8, 2023, 4:05 PM EDT - 2 years ago

Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023

Aug 1, 2023, 4:05 PM EDT - 2 years ago

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Jun 26, 2023, 9:00 AM EDT - 2 years ago

NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS

May 23, 2023, 9:00 AM EDT - 3 years ago

CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS

May 15, 2023, 9:00 AM EDT - 3 years ago

CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS

May 9, 2023, 4:05 PM EDT - 3 years ago

Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update

haha1978 Mar. 20 at 6:34 PM

$CPIX IPF has been updated on the NIH website. Looks like January of next year 2027 its completed. https://clinicaltrials.gov/study/NCT05571059?tab=study

1 · Reply

haha1978 Mar. 20 at 6:30 PM

$CPIX SCL study is not due till May 2026. https://clinicaltrials.gov/study/NCT02682511

1 · Reply

BioResearcher Mar. 20 at 6:05 PM

0 · Reply

BioResearcher Mar. 20 at 5:32 PM

$CPIX Vol is only 14K so far. I think this stock is mainly traded by the winners from CAPR :-) Like @haha1978 and few others. :-)

0 · Reply

haha1978 Mar. 19 at 7:21 PM

$CPIX 3.00 tomorrow or therabouts would be a great end to the week for a spinning top. The algorithm painting the tape for next week.

1 · Reply

BioResearcher Mar. 19 at 1:50 PM

$CPIX Oops ! spoke too soon. someone just woke up and dumped some shares to make it red now. Biotech stocks are getting killed lately, not only this one.

1 · Reply

BioResearcher Mar. 19 at 1:47 PM

$CPIX only green stock today !

0 · Reply

2pumps1dump Mar. 19 at 8:56 AM

$CPIX thought this was close

0 · Reply

BioResearcher Mar. 18 at 7:55 PM

$CPIX Without funding, I think they are likely to put the DMD drug on the shelf. Good OLE DMD data is likely to spike SP, but they don't publish it, Why ? Transparency is in question here.

1 · Reply

haha1978 Mar. 18 at 5:48 PM

$CPIX also market cap is around or below 40 million. If revenue can hit 55 to 60 million this year and be profitable thst could justify 5 to 8 dollars. Excluding ifetroban.

1 · Reply

haha1978 Mar. 18 at 4:59 PM

$CPIX 3 weeks red candles. So far last is either going to be an inverted hammer or maybe a spinning top and indicates 70% chance of reversal. Algorithm doesnt want to sell shares down here. Bought 2900 at 2.93 and it moved ask up to 3.04.

0 · Reply

BioResearcher Mar. 17 at 8:18 PM

$CPIX Management released a PR just to brag about a new website ???!!! really ?

1 · Reply

haha1978 Mar. 17 at 1:35 PM

$CPIX Not the Ifetroban. $XBI $IBB $QQQ https://finviz.com/news/337974/cumberland-pharmaceuticals-launches-new-sancuso-website-featuring-educational-resources-for-chemotherapy-induced-nausea-and-vomiting

1 · Reply

Dogfon Mar. 17 at 7:51 AM

$CPIX why is cumberland waiting so long to start the phase 3 study of iferbron in DMD cardiomyopathy?

1 · Reply

2pumps1dump Mar. 12 at 9:18 PM

$CPIX

0 · Reply

2pumps1dump Mar. 12 at 9:17 PM

$CPIX https://archive.fast-edgar.com/20260312/ARZZS22CZ22IC2Z2222R22ZBFLSQZZ282Z82/cmb26-0398992025annualrepo.pdf

0 · Reply

BioResearcher Mar. 12 at 8:06 PM

$CPIX The only green stock in my portfolio today :-)

0 · Reply

haha1978 Mar. 12 at 2:32 PM

$CPIX it was 4.1% placebo vs 6.2% control an average of 10% improvement with some outliers by up to 40%.

0 · Reply

haha1978 Mar. 12 at 2:19 PM

$CPIX in general the asprin study was weak for fatty liver it was 6% improvement. Ifetroban is definitely needed for a p2 trial for fatty liver. https://blogs.the-hospitalist.org/content/low-dose-aspirin-reduces-liver-fat-inflammation-markers#:~:text=At%20baseline%2C%2036.3%25%20of%20all,and%20liver%20stiffness%20by%20VCTE.

0 · Reply

haha1978 Mar. 12 at 2:10 PM

$CPIX new study out showing aspirin can reduce fatty liver by 40%. Makes you wonder how much better ifetroban would be if its 10x stronger. They should pursue the fatty liver after DMD.

0 · Reply

BioResearcher Mar. 12 at 1:13 PM

$CPIX Ifetroban and Aspirin have potential to prevent cancer from spreading by acting on TXA2. I just found that The scientists are running a big phase 3 trial using low-dosed Aspirin: "Add-Aspirin" Maybe that is the reason BP are not interested in Ifetroban. because Ifetroban will be against a generic drug. "Add-Aspirin is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India. It will recruit 11,000 participants to help find out whether regular aspirin use after treatment for an early stage cancer can prevent the cancer from coming back and preventing deaths."

1 · Reply

haha1978 Mar. 10 at 8:37 PM

$CPIX 50 million market cap. This coukd be the shake before IPF data release. No reason for this far a drop 38%.

1 · Reply

Market Cap	41.88M
Revenue (ttm)	44.52M
Net Income (ttm)	-2.84M
EPS (ttm)	N/A
PE Ratio	31.11
Forward PE	N/A
Profit Margin	-6.38%
Debt to Equity Ratio	0.21

Volume	53,000
Avg Vol	169,444
Day's Range	N/A - N/A
Shares Out	14.96M
Stochastic %K	20%
Beta	-0.58
Analysts	Strong Buy
Price Target	$8.50